The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Malay...

ONE-DAYMD RESOURCE HUB GLP-1 medicines, peptide therapies, emerging incretin drugs and research peptides explained in one evidence-focused library. GLP-1 drugs have moved from a diabetes niche into one of the most important areas of modern metabolic medicine. At the same time, interest has expanded into amylin analogs, GIP/GLP-1 combinations, triple agonists, growth-hormone-related peptides, regenerative peptides and other experimental compounds. This resource hub is designed to help readers distinguish between approved medicines , investigational therapies , and research-use compounds . Evidence, regulatory status and safety should always be evaluated for the specific molecule, indication, dose, route of administration and patient population. Start Here GLP-1 Medicines Next-Generation Incretins Major Peptide Medicines Research Peptides Safety Evidence Directory FAQ Edito...